ABC008

Abcuro, Inc. · Phase 2 active Small molecule

At a glance

Generic name	ABC008
Sponsor	Abcuro, Inc.
Modality	Small molecule
Phase	Phase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

A Study to Evaluate the Efficacy and Safety of ABC008 for Inclusion Body Myositis (PHASE2, PHASE3)
Long-term Extension Study of Ulviprubart (ABC008) in Subjects With Inclusion Body Myositis (PHASE2, PHASE3)
A Phase 1 Study of ABC008 in Ascending (Single Ascending Dose/Multiple Ascending Dose) Study in Patients With (IBM) (PHASE1)
ABC008 in Subjects with T-cell Large Granular Lymphocytic Leukemia (T-LGLL) (PHASE1, PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

ABC008 CI brief — competitive landscape report
ABC008 updates RSS · CI watch RSS
Abcuro, Inc. portfolio CI